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Abstract
Non-melanoma skin cancer is the most frequent type of cancer in humans. In this study we demonstrate that elevated
IKKa expression in murine epidermis increases the malignancy potential of skin tumors. We describe the generation of
transgenic mice overexpressing IKKa in the basal, proliferative layer of the epidermis and in the outer root sheath of hair
follicles. The epidermis of K5-IKKa transgenic animals shows several alterations such as hyperproliferation, mislocalized
expression of integrin-a6 and downregulation of the tumor suppressor maspin. Treatment of the back skin of mice with
the mitogenic agent 12-O-tetradecanoylphorbol-13-acetate causes in transgenic mice the appearance of different
preneoplastic changes such as epidermal atypia with loss of cell polarity and altered epidermal tissue architecture, while
in wild type littermates this treatment only leads to the development of benign epidermal hyperplasia. Moreover, in skin
carcinogenesis assays, transgenic mice carrying active Ha-ras (K5-IKKa-Tg.AC mice) develop invasive tumors, instead of
the benign papillomas arising in wild type-Tg-AC mice also bearing an active Ha-ras. Therefore we provide evidence for a
tumor promoter role of IKKa in skin cancer, similarly to what occurs in other neoplasias, including hepatocarcinomas and
breast, prostate and colorectal cancer. The altered expression of cyclin D1, maspin and integrin-a6 in skin of transgenic
mice provides, at least in part, the molecular bases for the increased malignant potential found in the K5-IKKa skin
tumors.
Citation: Alameda JP, Moreno-Maldonado R, Fernández-Aceñero MJ, Navarro M, Page A, et al. (2011) Increased IKKa Expression in the Basal Layer of the
Epidermis of Transgenic Mice Enhances the Malignant Potential of Skin Tumors. PLoS ONE 6(7): e21984. doi:10.1371/journal.pone.0021984
Editor: Christophe Egles, Université de Technologie de Compiègne, France
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Introduction
Keratinocytes of the basal layer of the epidermis are mitotic,
providing new cells to replace those that are shed. After moving to
the suprabasal layers, the cells gradually differentiate and give rise to
the cornified layer at the surface of the skin that protects the internal
organs. Therefore, a balance between keratinocyte proliferation and
differentiation is required to maintain epidermal homeostasis.
IKKa (IkB kinase a) is a fundamental component of the IKK
complex that regulates the NF-kB signalling pathway [1–3]. IKKa
has a fundamental role in regulating keratinocyte proliferation and
differentiation [4–8]. The epidermis of IKKa2/2 newborn mice
lacks a terminally differentiated cornified layer and exhibits marked
thickening [6–8]. Reintroduction of IKKa or a kinase-inactive
mutant IKKa induces terminal differentiation of keratinocyte and
represses hyperproliferation [9,10]. This demonstrates that IKKa is
necessary for epidermal differentiation independently of its kinase
activity [9]. We have described that IKKa increases the
differentiation of human keratinocytes by a mechanism dependent
on E-cadherin [5]. Other adhesion molecules such as claudin-23,
occludin and desmoglein 3 have also been found to be regulated by
IKKa and to play a role in epidermal terminal differentiation and
skin barrier function [11].
Non melanoma skin cancer (NMSC) is the most common
malignancy in humans: BCCs (basal cell carcinomas) and SCCs
(squamous cell carcinomas) represent the vast majority of the
tumors diagnosed. The incidence of both benign and malignant
NMSC has been rising at an alarming rate for the past several
years. The role of IKKa in cancer development remains
controversial: while it has been suggested that it functions as a
tumor suppressor in skin cancer [4,12,13], there are also evidences
that support a role of IKKa as promoter of cancer progression and
metastasis in different types of neoplasias such as breast cancer
[14], hepatocarcinomas [15], prostate cancer [16,17] and
colorectal cancer [18,19]. Indeed, we have found, in xenograft
assays, an increase in malignancy of skin tumors over-expressing
IKKa [5].
In the last years it has been found that IKKa regulates the
expression of molecules implicated in cancer development such as
the tumor suppressor maspin (mammary serine protease inhibitor),
twist, and adhesion proteins. It inhibits cellular motility, invasi-
veness and angiogenesis, and provides sensitivity to apoptosis in
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tumor cells [20,21]. Maspin expression predicts a better prognosis
in different types of cancers: breast [22,23], prostate [24,25], colon
[26], oral squamous cell carcinoma [27], lung [28], larynx [29],
malignant melanoma [30] and ovarian cancer [31], although
recently it has been reported that it might act as tumor promoter
in colorectal or pancreatic cancers [32,33]. Maspin also acts as a
suppressor of metastasis in different types of cancer such as
prostate, liver and breast [17,34]. Interestingly, IKKa inhibits
maspin expression and promotes cell metastasis in prostate cancer
and hepatocarcinomas [15,17,35]. Twist is a basic-helix-loop-helix
(bHLH) protein known to be essential during the embryogenesis
which also plays an important role as mediator of EMT (epidermal
mesenchymal transition) during tumor progression [36]. Twist is
overexpressed in a large set of human and murine tumors
including sarcomas, melanomas, gliomas and neuroblastomas
[37,38] being the reactivation of Twist indicative of poor
prognosis. Interestingly, it has been reported that IKKa null
embryos express reduced levels of Twist [7] which suggest a
positive regulation of Twist expression by IKKa. The altered
expression of adhesion molecules has been related to tumor
development, included skin cancer, i.e., overexpression of the
adhesion protein integrin-a6 in the basal layer of epidermis and
hair follicles has been reported to cause malignization of skin
tumors in transgenic mice [39]. Moreover, a6b4 integrin
expression in suprabasal strata serves as an early predictive
marker to identify benign squamous tumors at high risk of
malignant progression [40].
In this work we have analyzed the effect of increased levels of
IKKa expression in the basal layer of the epidermis of transgenic
(Tg) mice (K5-IKKa mice), and its repercussion in in vivo skin
carcinogenesis. We have found that K5-IKKa mice exhibit in
epidermis several alterations, such as increased proliferation,
suprabasal integrin-a6 expression and downregulation of the
tumor suppressor maspin. In line with these alterations, the
application of a mitogenic agent, i.e. TPA in the back skin of mice
leads in transgenic K5-IKKa mice to the appearance of
preneoplastic features such as epidermal atypia with loss of cell
polarity and altered epidermal tissue architecture, while in wild
type (WT) littermates this treatment only leads to the development
of benign epidermal hyperplasia. Moreover, in carcinogenesis
experiments, tumors developed in transgenic mice carrying active
Ha-ras (Tg.AC mice) are invasive tumors, in sharp contrast with
the benign tumors originated in WT animals (also bearing an
active Ha-ras). In addition to integrin-a6 suprabasal overexpres-
sion, tumors developed in the K5-IKKa mice show reactivation of
the expression of Twist.
Materials and Methods
Ethics Statement
All experimental procedures were performed according to
European and Spanish laws and regulations (European Conven-
tion ETS 123 on the use and protection of vertebrate mammals
used in experimentation and other scientific purposes; Spanish
R.D 1201/2005 of the Ministry of Agricultural, Food and
Fisheries on the protection and use of animals in scientific
research) and approved by the our institution’s ethics committee.
Approval ID: BME 3/06; BME 1/09 and BME 2–10 by the
CIEMAT Institution’s ethics commitee.
Generation of Tg mice
HA-tagged murine IKKa [5] was placed under the control of a
5.2 kb 59-upstream fragment of bovine K5 promoter and a rabbit b-
globin intron (Figure 1A). Tg mice were generated by microinjec-
tion of this construct into B6D2F2 embryos using standard
techniques and Tg lines were maintained by crossing with
B6D2F1 mice. Mice were genotyped by PCR analysis of tail
genomic DNA using primers specific for the rabbit b-globin intron.
Wild type non-transgenic littermates were used as control animals.
Western Blotting
Total or nuclear and cytoplasmic protein extracts (40 mg) were
subjected to SDS/PAGE. The separated proteins were transferred to
nitrocellulose membranes (Amersham, Arlington Heights, IL) and
probed with antibodies against IKKa, IKKb, IKKc (IMGENEX,
San Diego, CA, USA); HA epitope (Covance, California, USA);
IkBa, p105/p50, p65, maspin, actin, fibrillarin, EGFR (Santa Cruz
Biotechnology, Inc. Europe); p100/p52 (Abcam, Cambridge, UK);
P-p65, P-IkBa (Cell Signaling Technology, Danvers, MA, USA);
Cyclin D1 (NeoMarkers, Fremont, CA, USA); P-tyrosine (4G10;
Upstate, NY, USA), and tubulin (Sigma, Saint-Louis, Missouri,
USA). In all cases samples were subjected to luminography with the
Supersignal West Pico Chemiluminescent Substrate (Pierce Biotech-
nology, Inc., Illinois, USA). Densitometric analysis of the blots was
performed using the Molecular Analyst software package (Bio-Rad
Laboratories Inc., Hercules, California, USA).
Histology and Immunohistochemistry
Skin and tumors were fixed in 10% buffered formalin or in 70%
ethanol and embedded in paraffin. Sections were stained with
H&E for histopathological evaluation or used for immunostaining
using primary antibodies raised against IKKa (sc-7182, Santa
Cruz Biotechnology, Inc. Europe; IMG-90454, IMGENEX),
keratin K1, K5, K10, involucrin, loricrin, filaggrin (Covance);
keratin K13, Twist (Abcam); integrin-a6 (CD49f; BD Pharmin-
gen), BrdU (Roche, Mannheim, Germany) and Cleaved Caspase-3
(Cell Signaling Technology, Danvers, MA, USA). Sections were
incubated with a biotinylated anti-mouse, anti-rat or anti-rabbit
antibody, and then with streptavidin conjugated to horseradish
peroxidase (DAKO A/S, Glostrp, Denmark). Antibody localiza-
tion was determined using 3,3-diaminobenzidine (DAB) in PBS
(Vector Laboratories; Burlingame, CA, USA).
BrdU treatment
Mice received an intraperitoneal injection of BrdU 120 mg/kg
body weight 1 h before sample harvesting.
TNF-a in vivo treatment
3 days-old mice were subcutaneously injected with 20 mg/Kg of
human TNF-a (Sigma) or with PBS (control). After the indicated
times mice were sacrificed, skin samples removed and proteins
extracted.
NF-kB activity assay
NF-kB DNA binding assays was determined by the NF-kB
p50/p65 EZ-TFA Transcription Factor Assay (Millipore, Massa-
chusetts, USA) following manufacturer’s instructions [41]. Briefly,
protein extracts from WT and Tg skins (12.5 mg) were mixed with
a double stranded biotinylated oligonucleotide containing the
consensus sequence for NF-kB binding. In this way, activated NF-
kB (active p65) contained in the extracts binds to its consensus
sequence. This mixture is transferred to a streptavidin coated plate
and the bound NF-kB subunit, p65, is detected with a specific
primary antibody. An HRP-conjugated secondary antibody is then
used for detection and provides sensitive colorimetric detection
that can be read in a spectrophotometric plate reader (Genios Pro,
TECAN, Madrid, Spain; XFluor4Version V4.50).
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Figure 1. Characterization of K5-IKKa transgenic mice. (A) Recombinant DNA construct employed to generate transgenic mice. (B) Western
blots showing IKKa and HA expression in WT and 3 different transgenic lines (L1, L3 and L5). Actin was used as a loading control. (C) Expression of the
IKKa protein in back skin of 3-day-old mice. Immunostaining with the Sc-7182 antibody is showed (middle and right panels); similar results where
obtained with the IMG-90454 anti IKKa antibody (not shown). Control without primary antibody (only with secondary biotinylated anti-rabbit
antibody) is shown as control of specificity of the immunostaining against IKKa (left panel). Arrows show the expression of IKKa in basal epidermal
keratinocytes and hair follicles. Asterisks indicate cytoplasmic expression of IKKa. (D) IKKa and HA detection in nuclear and cytoplasmic protein
extracts from 5 day-old WT and Tg mice. Samples from two different mice of the line L1 and two different control littermates were loaded. Fibrillarin
and tubulin show loading control and purity of the extracts. (E) Western blots analysis of the expression of different members of the NF-kB pathway
in skin of WT and K5-IKKa transgenic mice. Total proteins from backskin of two different mice of the line L1 and two different control littermates were
loaded. No differences were found between mice of both genotypes. (F) Western blot showing p100 and p105 processing in skin of WT and Tg mice.
No differences were found. (G) Western blot showing the nuclear localization of p52 in skin of WT and Tg mice. No differences were found. (H) p65
and IkBa phosphorylation kinetics; actin: loading control. Newborn WT and Tg mice were injected with TNF-a and analyzed at the indicated times. (I)
NF-kB activity in skin of non-stimulated and TNF-a injected mice for the indicated times. Experiments were repeated 3 times with similar results.
doi:10.1371/journal.pone.0021984.g001
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TPA treatment
To induce epidermal hyperplasia, six K5-IKKa 8-week-old
mice and six WT mice of the same age (8 weeks) were used.
Shaved dorsal skins were treated twice a week with 5 mg of 12-O-
tetradecanoylphorbol-13-acetate (TPA; Sigma) for 3 weeks. Mice
were sacrificed 24 hours after the last application.
Carcinogenesis assays
In the DMBA/TPA protocol, both, K5-IKKa and WT 9-week-
old mice (9 animals respectively) were initiated with a single dose
of 200 nmol of 7,12-dimethyl-benz[a]anthracene (DMBA) (Sigma)
on shaved dorsal skin. Two weeks later, tumor growth was
promoted by treating with 5 mg of TPA twice a week per 20 weeks.
In the carcinogenesis experiments in Tg.AC background, female
homozygous v-Ha-ras transgenic Tg.AC mice [42] were mated
with K5-IKKa males. Double transgenic K5-IKKa-TgAC and
WT-TgAC 9-week-old mice (11 animals respectively) were treated
twice weekly with topical applications of 5 mg of TPA in 200 ml
acetone for 7 weeks according to standard protocols. Experimental
procedures were performed according to European and Spanish
laws on experimental animal protection.
Statistics
Statistical significance of data was assessed using the t-test and
the Mann-Whitney (Wilcoxon) W test.
Results
Increased expression of IKKa in basal keratinocytes of
K5-IKKa transgenic mice
We generated the K5-IKKa transgenic mice overexpressing a
mouse IKKa cDNA tagged with an epitope from hemagglutinin A
(HA) (Figure 1A). The keratin 5 (K5)-derived sequences included
in this construct drive transgene expression to the basal cells of the
epidermis and outer root sheath (ORS) of hair follicles, as well as
to internal stratified epithelia [43,44]. K5-IKKa transgenic mice
developed normally and showed no obvious alterations. Immu-
noblotting analysis using specific antibodies against IKKa revealed
increased expression of IKKa in the skin of different K5-IKKa Tg
lines (Figure 1B). HA epitope was detected in skin of K5-IKKa-Tg
mice but not in skin of WT mice (Figure 1B). L1 and L3 were the
highest IKKa expressing lines and similar results were obtained in
the analysis of both of them, therefore we performed most of the
following experiments in line L1. The immunohistochemical
staining of IKKa in back skin of WT and Tg mice showed higher
IKKa staining in the basal layer of the epidermis and the ORS of
hair follicles of K5-IKKa-Tg mice than in WT littermates
(Figure 1C). IKKa immunostaining was performed with two
different antibodies (see Mat and Met section) and repetitively
IKKa expression was detected both in the cytoplasm and in the
nucleus of suprabasal and basal keratinocytes in WT and Tg
animals (Figure 1C). WB analysis confirmed this nuclear and
cytoplasmic localization of IKKa and also its overexpression in
K5-IKKa-Tg skin (Figure 1D). HA immunostaining gave similar
results (data not shown).
Classical and non-canonical NF-kB activation pathways
are not affected in the K5-IKKa-Tg mice
The state of the NF-kB pathway in WT and K5-IKKa mice
was analyzed. In agreement with other studies [8], we found that
changes in IKKa expression do not alter the expression of other
members of the NF-kB pathway such as IKKb, IKKc, IkBa and
p65 (Figure 1E). In addition no differences were found in p100 or
p105 processing, nor in nuclear p52 localization in WT and Tg
mice skin (Figure 1F, G), indicating that the non-canonical
pathway of NF-kB does not seem altered by IKKa overexpression.
Treatment of newborn mice with tumor necrosis factor a (TNF-a)
led to similar kinetics and extension of p65 and IkBa
phosphorylation in WT and Tg mice (Figure 1H). In addition,
we analyzed the NF-kB pathway by measuring NF-kB binding
activity in protein extracts from skins of mice of each genotype and
found no differences in non-stimulated skin as well as after TNF-a
subcutaneous injection of WT and K5-IKKa mice (Figure 1I).
Together, these results indicate that the classical IKK/NF-kB
pathway is not modified in K5-IKKa Tg mice, and are in
accordance with our previous data in human HaCaT keratino-
cytes [5] where the overexpression of IKKa did not alter this
signalling pathway.
Delocalized integrin-a6 suprabasal expression, increased
proliferation and maspin inhibition in epidermis of K5-
IKKa-Tg mice
As IKKa has an essential role in epidermal morphogenesis and
differentiation, we analyzed early and late differentiation markers
of the epidermis such as K1, involucrin, loricrin, and filaggrin
(Figure 2A). No appreciable differences were found between WT
and K5-IKKa-Tg mice, suggesting that no alterations of the
normal epidermal differentiation program occur in these animals.
The expression of K5 and K6 also was unaltered (data not shown).
We also analyzed the proliferative capability of WT and K5-
IKKa-Tg mice skin by measuring BrdU incorporation. We
observed increased BrdU-positive cells in the basal layer of the
epidermis of K5-IKKa mice (11.462.7% in Tg mice versus
7.661.7% in WT mice; n = 6; P,0.05) (Figure 2B). Cyclin D1,
another marker of proliferation was also increased in the skin of
Tg mice (Figure 2C). In an attempt to discover a possible cause for
the increased proliferation observed in skin of transgenic mice, we
measured EGFR expression, as this is an important factor for
keratinocyte proliferation [45]; however, we found no differences
in EGFR levels nor in EGFR phosphorylation in skin of WT and
K5-IKKa Tg mice (Figure 2D). Another reason for the increase in
the number of proliferating cells in the skin of Tg mice could be
the altered expression of adhesion molecules; in particular, the
suprabasal expression of integrin-a6 has been found to be
associated with hyperproliferative conditions in dermal equivalent
cultures of keratinocytes [46]. We therefore analyzed the
expression of integrin-a6 in the back skin of WT and Tg newborn
mice and found that while WT mice skin exhibit integrin-a6
expression restricted to the basal layer of the epidermis, K5-IKKa-
Tg mice showed increased and delocalized integrin-a6 expression
in basal as well as suprabasal keratinocytes (Figure 2B). As these
parameters (i.e. increased proliferation and altered expression of
integrin-a6 in epidermis) are signals that may precede a
malignization process [39], we checked the expression of maspin,
a tumor suppressor known to be negatively regulated by IKKa.
We found by Western blotting of total skin extracts that maspin
was downregulated in the skin of K5-IKKa-Tg mice (Figure 2C),
in agreement with other studies where IKKa overexpression leads
to the inhibition of maspin expression [15,17].
Epidermal atypia of the epidermis in K5-IKKa transgenic
mice treated with TPA
To analyze whether the alterations found in the skin of
transgenic K5-IKKa mice could predispose these mice to the
development of more severe lesions when subjected to skin insult,
we applied multiple doses of the mitogenic agent, TPA, to the back
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skin of WT and Tg mice in the second telogen phase of the hair
follicles. As expected, 3 weeks of treatment provoked in WT
animals the entry of hair follicles into the anagen phase as well as
the development of epidermal hyperplasia (7 to 10 layers of
epidermal keratinocytes versus 2 to 4 layers observed in non-treated
epidermis of adult mice; Figure 3 compare A and B). We observed
that the hyperplasia was due to an increase both in the stratum
spinosum and granulosum (see inset in B). This hyperplasia exhibit the
typical increase in epidermal thickness, with keratinocytes of the
stratum basale containing nuclei perpendicular to the basal
membrane; keratinocytes of the stratum spinosum with round,
central nuclei; and keratinocytes of the stratum granulosum showing
progressive flattening of the cells, in parallel to the basal
membrane, with smaller nucleus and scarce cytoplasm filled with
keratohyaline granules. In Tg mice, TPA application also induces
hair follicle anagen phase and epidermal hyperplasia (Figure 3
compare C and D). However, in these mice the hyperplasia was
associated with epidermal atypia, characterized by a disorganized
architecture of the different keratinocyte layers where cells lose
their polarity and normal differentiation; it was not possible to
distinguish the stratum basale, spinosum and granulosum because most
keratinocytes appeared as round cells with central nucleus and
there was no sign of terminal differentiation (i.e. lack of
keratohyaline granules in the upper suprabasal layers) (see inset
in Figure 3D and compare with inset in B). There was also a great
heterogeneity in the nuclear staining of keratinocytes from Tg-
TPA-treated mice showing many condensed, highly basophilic
pyknotic nuclei. Elevated rates of keratinocyte proliferation
Figure 2. Alterations found in back skin of K5-IKKa-Tg mice. (A) Immunohistochemical analysis of epidermal differentiation markers in back
skin of 3-day-old WT and K5-IKKa mice. No differences were found between mice of both genotypes. B, SB, basal and suprabasal keratinocyte layers
respectively. (B) Images show the increased number of basal keratinocytes that incorporate BrdU in epidermis of Tg mice. Integrin a6 is expressed in
basal as well as suprabasal keratinocytes in skin of Tg mice. (C; D) Analysis of cyclin D1 (Cyc D1), maspin and EGFR protein levels as well as EGFR
phosphorylation (P-EGFR) in total protein extracts of skin of WT and K5-IKKa-Tg mice. Total proteins from backskin of two different mice of the line L1
and two different control littermates were loaded.
doi:10.1371/journal.pone.0021984.g002
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(measured as BrdU incorporation) were observed in the epidermis
of both WT and Tg mice treated with TPA (Figure 3 E, F), being
significantly higher the number of proliferating cells in the K5-
IKKa mice (Figure 3F) compared with WT siblings (Figure 3E)
(labelling index, Tg = 29.163.7; WT = 18.864.0; n = 6; P,0.05).
The treatment with TPA in addition to a mitogenic effect also
provokes an inflammatory response. We have analyzed this effect
in skin of WT and transgenic mice and have found a similar
response in both cases i.e. a mild lichenoid inflammation with
diffuse infiltrates of mononuclear cells in the superficial dermis
(Figure 3B and D asterisks).
Enhanced malignant potential of tumors developed in
K5-IKKa transgenic mice
We performed two different approaches to investigate the
susceptibility of K5-IKKa mice to develop skin cancer. We
initiated WT and K5-IKKa mice with a single dose of DMBA
followed by TPA application in a conventional two-stage (DMBA/
TPA) tumorigenesis protocol. DMBA activates Ha-ras to initiate
skin tumors [47]. During the course of the experiment we did not
observe significant differences in the number of tumors between
WT and Tg mice (Figure S1A). Tumors were traced until week 27,
when they were collected. The average tumor size was also similar
in both groups (data not shown). In the other approach we
performed TPA treatments in F1 crosses of K5-IKKa mice with
the Tg.AC mice strain, carrying an activated Ha-ras transgene that
triggers the classic initiation event [42,44,48]. Both groups of mice
(WT-TgAC and K5-IKKa-TgAC) developed papillomas with a
similar latency period (5–7 weeks, Figure S1B). The percentage of
animals that developed tumors, as well as the tumor multiplicity,
was similar in both genotypes. From week 17 on, the number of
tumors in WT mice in both approaches was reduced, due
probably to a higher regression rate (Figure S1A, B).
Figure 3. Atypical epidermal hyperplasia in skin of K5-IKKa-Tg mice subjected to TPA treatment. (A–D) Representative paraffin-sections
of skin from WT (A–B) and K5-IKKa-Tg mice (C–D) were stained with hematoxilin/eosin. (A, C) Non-treated skins; (B, D) TPA treated skins. (B)
Hyperplastic epidermis induced by topical application of TPA in WT mice. White arrow indicates a hair follicle in the anagen phase. (Inset in B) B:
stratum basale, S: stratum spinosum, G: stratum granulosum. Conservation of squamous differentiation is clear in WT epidermis where marked
hyperplasia of stratum spinosum (acantosis) and stratum granulosum (hipergranulosis) are observed as common facts of typical epidermal hyperplasia.
(D) Hyperplasia and epidermal atypia with loss of cellular architecture in TPA-treated Tg skin. White arrows indicate hair follicles in the anagen phase.
(Inset in D) Epidermal hyperplasia in K5-IKKa-Tg mice shows an atypical proliferating epithelium with all strata conformed by keratinocytes with
round, central nuclei highly basophilic (pyknosis). The stratum granulosum of flattened cells with cytoplasm filled with keratohyaline granules were
not formed. Asterisks in B, D points to regions of the lichenoid inflammation with diffuse infiltrates of mononuclear cells found in skin of both WT and
Tg mice after TPA treatment. (E, F) BrdU incorporation in skins from WT (E) and Tg (F) mice treated with TPA. (A–F): scale bars = 50 mm.
doi:10.1371/journal.pone.0021984.g003
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We checked by Western blot analysis that the tumors
developed in Tg mice in both carcinogenesis protocols express
higher levels of IKKa than WT tumors and also express the HA-
tag (Figure 4A, F). The histological study showed important
differences between tumors developed in WT and K5-IKKa
mice in the two approaches. Thus, while tumors arising in WT
mice in the DMBA/TPA tumorigenesis were benign papillomas
with a well conserved differentiation pattern of the epidermis
(Figure 4B, C), those developed by K5-IKKa mice exhibited
extended areas of epithelial atypia (Figure 4D, E), indicating a
higher malignant potential. These lesions resemble those found
in the epidermis of Tg mice treated with TPA (Figure 3D)
although of higher aggressive potential. The tumorigenesis assays
in Tg.AC mice showed that tumors from WT-TgAC animals
were benign papillomas (Figure 4G, H), while tumors from K5-
IKKa-TgAC mice showed areas of focal invasion, i.e.,
microinvasive infiltration, indicating a higher degree of malig-
nant progression (Figure 4I, J). The immunohistochemical
analysis of tumors developed in WT mice in both types of
carcinogenesis protocols showed a diffuse expression of IKKa in
the suprabasal cells (Figure 5A). By contrast, a higher staining for
IKKa was detected in the K5-IKKa tumors obtained by both
approaches (Figure 5A’), in accordance with the results of the
Western blot analysis of IKKa in tumors (Figures 4A and F).
IKKa was mainly located in the basal cells, where the K5
promoter directs the transgene expression although it was also
detected in the suprabasal layers (Figure 5A’ inset). Differenti-
ation markers such as the keratins K1/K10 are expressed at
higher levels in WT tumors than in Tg tumors in both protocols
of skin carcinogenesis (Figure 5B, B’ and data not shown). K13, a
keratin characteristic of internal stratified squamous epithelia
which is aberrantly expressed in skin tumors (Figure 5C),
indicating malignancy [49], was rarely expressed in WT tumors
while it was extensively expressed in the K5-IKKa tumors
(Figure 5C’). Low expression of keratins K1/K10 and elevated
expression of K13 indicate a worse prognosis of tumors that
express elevated levels of IKKa. Maspin expression was analyzed
and found that it was lower in the K5-IKKa tumors (Figure 5D,
D’). Panels A–D’ in Figure 5 show staining of DMBA/TPA
tumors although similar results were found in the Tg.AC tumors
staining (data not shown).
Induction of twist and delocalized integrin-a6 expression
in tumors developed in K5-IKKa Tg mice. We analyzed
other markers of tumor progression, such as the expression of
integrin-a6. In benign tumors, integrin-a6 is expressed by basal
keratinocytes; however in malignant tumors it is also expressed in
suprabasal layers [40,48]. We found that tumors developed in WT
mice in both carcinogenesis protocols have a basal staining of
integrin-a6 (Figure 5E); by contrast, tumors from K5-IKKa mice
exhibit basal as well as delocalized suprabasal expression of
integrin-a6 (Figure 5E’).
Another marker of tumor malignancy is Twist, which is
expressed in embryonic development and silenced in the
adulthood. However, it is induced in malignant tumors and is
associated with metastasis [36]. We found that while WT tumors
do not express Twist (Figure 5F), it is highly induced in K5-IKKa
tumors obtained by both protocols of carcinogenesis (Figure 5F’).
It is detected in the basal layer of the epidermis, where the K5
promoter directs the expression of the IKKa transgene
(Figure 5F’).
As increased integrin-a6 expression is usually accompanied by
increased proliferation [46], we next analyzed tumor cell
proliferation, measured as BrdU incorporation, and found higher
number of proliferating cells in the K5-IKKa tumors (Figure 5G,
G’). However, the size of IKKa and WT tumors showed no
significant differences; therefore, we examined the apoptosis in
both types of tumors and found that WT papillomas exhibited low
number of apoptotic cells (measured by cleaved-Caspase 3
immunostaining; Figure 5H). By contrast, the number of apoptotic
cells in IKKa tumors was markedly higher (Figure 5H’).
Nevertheless, the rate of proliferation is greater than that of
apoptosis in transgenic tumors and these differences alone would
not fully explain the similar size reached by both types of tumors.
Panels E–H’ in Figure 5 show staining of DMBA/TPA tumors
although similar results were found in the Tg.AC tumors staining
(data not shown). Altogether these results suggest that skin tumors
overexpressing IKKa in the basal layer of the epidermis have a
malignant potential due at least in part to the induction of Twist
expression and the suprabasal expression of integrin-a6.
Discussion
We have found that the overexpression of IKKa in the
epidermis of K5-IKKa mice causes several molecular alterations,
such as increased cyclin D1 expression, delocalized suprabasal
integrin-a6 expression and downregulation of the tumor suppres-
sor maspin. These proteins are important for cancer development
and progression, suggesting that the skin of these Tg mice could
develop more aggressive lesions when subjected to skin injuries
than WT skin. We have proved that in fact, after applying
proliferative stimuli (such as TPA) in back skin, K5-IKKa mice
develop epidermal atypia with loss of tissue architecture, being
these pathological changes considered as preneoplastic signals.
TPA also induces inflammation; the inflammatory response found
both in WT and Tg mice following TPA treatment was similar,
indicating that the alterations found in skin of Tg mice after TPA
application are unlikely due to the proinflammatory activity of this
agent. We have also found that in carcinogenesis assays Tg mice
develop invasive tumors with higher malignant potential than the
benign tumors developed in WT mice.
The first anomaly detected in the epidermis of the Tg K5-IKKa
mice was an enhanced proliferation of basal keratinocytes that
seems to be the consequence of both enhanced cyclin D1
expression and increased (and delocalized) integrin-a6 expression.
Epidermal suprabasal integrin-a6 expression has been correlated
with high proliferative activity in the basal layer of the epidermis,
without occurrence of abnormal terminal differentiation or
inflammation [46]. Our results are in line with these observations,
since we find in K5-IKKa Tg mice increased proliferation of
keratinocytes without inflammation or appreciable alterations in
early or terminal differentiation. While our data are the first
description of regulation of integrin-a6 by IKKa, the regulation of
the expression of other adhesion proteins by IKKa has been
previously reported: Changes in E-cadherin, desmoglein 3, claudin
and occludin expression levels as a consequence of changes in
IKKa expression have been described [5,11,50]. The induction of
cyclin D1 expression by IKKa has also been previously reported
[51]; in addition, we have also found increased cyclin D1
expression in human keratinocytes overexpressing IKKa (Alame-
da et al, unpublished data).
The suprabasal integrin-a6 expression found both in epidermis
and skin tumors of Tg mice could also cause the increased skin
malignancy of K5-IKKa tumors, as inappropriate suprabasal
integrin-a6b4 expression in epidermis correlates with high risk of
cancer progression [39]. In this regard, it is interesting to note that
the delocalized integrin-a6 expression in papillomas is an early
predictive marker for the identification of benign squamous
tumors at high risk of malignant progression [40].
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An interesting finding of this study has been the discovery of
IKKa as negative regulator of the tumor suppressor maspin in the
skin, since downregulation of this protein has been related to
tumor progression and metastasis [17,20,21]. The downregulation
of maspin by IKKa in epidermis has not been described before
and we have confirmed this result in other different transgenic
mice expressing distinct IKKa constructs (Alameda et al,
unpublished results). Additionally, we have found that Twist
expression which is silenced in adult tissues is induced in K5-IKKa
tumors. In our experience searching in mouse skin cancer we have
analyzed by immunohistochemistry more than 80 skin tumors
obtained by both protocols of chemical carcinogenesis, and wee
have never found before the induction of Twist expression in
keratinocytes. Twist induction could be another plausible reason
for the increased aggressiveness of the K5-IKKa tumors
(developed in Tg.AC and DMBA-treated mice, carrying an
activated Ha-ras), since recent findings show that in the presence of
aberrant mitogenic signalling, such as Ha-ras activation, reactiva-
Figure 4. Tumors from K5-IKKa transgenic mice show increased malignancy. (A, E) Tumors developed in WT and Tg mice in the DMBA/TPA
skin carcinogenesis assays. (A) Western blot showing the expression of the transgene in the tumors. Total protein extratcs from two different tumors
developed in transgenic mice of the line L1 and proteins from two different control mice were loaded. (B–E) Histology of tumors arising in mice
subjected to the DMBA/TPA approach. Note the epithelial atypia areas in Tg tumors (inbox in E) versus the well conserved tissue architecture in WT
tumors (C). (F–J) Tumorigenesis in Tg.AC mice. (F) Western blot showing the expression of the transgene in the tumors. Total protein extratcs were
loaded. (G, H) Development of benign tumors in WT-TgAC mice versus invasive tumors K5-IKKa-TgAC mice (I, J). (J) High magnification showing the
rupture of the basement membrane and invasion of tumor epidermal cells into the stroma of transgenic tumors. Arrows in (I, J): focal invasion areas.
doi:10.1371/journal.pone.0021984.g004
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tion of Twist promotes the transition from a premalignant to a
malignant stage by inactivation of innate failsafe programs [38]. It
is well known that Twist is reactivated in different types of tumors
and it is considered to play a key role in the development and
progression of human cancer, being associated with advanced
tumor stage and poor prognosis in rhabdomyosarcoma, gastric
carcinoma, melanoma, glioma, liver carcinoma and breast,
prostate, bladder and pancreatic cancer [37;52,53;36,54]. The
regulation of Twist expression by IKKa has been previously
noted, in other context, by Takeda et al., who described the
downregulation of twist in IKKa2/2 embryos [7].
During the last years several evidences have been reported
indicating that IKKa functions as an oncogenic molecule. For
instance, IKKa phosphorylates important molecules of signalling
cascades (b-catenin, estrogen receptor-a transcriptional factor)
which through induction of cyclin D1 and/or c-Myc expression
enhances tumor proliferation [51,55,56,57]. Recently, a nuclear
function of IKKa has been implicated in tumor progression:
[58,59,19,60]. In this regard and in agreement with the data
obtained in this study, it is interesting to mention the role of
nuclear IKKa in promoting cancer through inhibition of maspin
expression in pancreatic cancer [17,35]. Other evidences of the
implication of IKKa in tumor promotion are that IKKa is
induced by different proangiogenic agents such as TPA, UV
radiation and Ets1 and that IKKa itself promotes angiogenesis
and stimulates tumoral growth [61]. In this context, it is worth to
note that IKKa KO mice have impaired angiogenesis [8]. In
agreement with all these data, there is an increasing number of
studies reporting the relationship of IKKa signaling to the
development of different types of neoplasias: breast cancer [14];
hepatocarcinomas [15]; prostate cancer [17], and colorectal
cancer [18]. Our group has also found an increase in the
malignancy of skin tumors arising after injection of tumor
epidermal cells overexpressing IKKa into nude mice [5].
On the other hand, other studies indicate a role for IKKa as a
tumor suppressor in skin cancer. Therefore, Loricrin-IKKa
transgenic mice that overexpress IKKa in the suprabasal
terminally differentiated cells, which are mitotically inactive and
committed to shed, develop less tumors in skin carcinogenesis
experiments than WT mice [4]. However, this approach is not
comparable to ours because we have targeted IKKa to basal
keratinocytes, which are mitotically active cells. This is an
Figure 5. Immunohistochemical analysis of tumor markers in WT and K5-IKKa DMBA/TPA tumors. (A, A’) IKKa is scarcely and diffusely
expressed in the suprabasal cells of WT tumors while it is strongly expressed in K5-IKKa tumors, mainly in the basal cells, although it is also detected
in the suprabasal cells. (B, B’) Elevated expression of K1 is detected in WT tumors while Tg tumors exhibit scarce K1 staining. (C, C’) K13
immunostaining shows that it is weakly expressed in WT tumors versus the strong expression detected in Tg tumors. (D, D’) Lower staining of Maspin
in K5-IKKa tumors. (E, E’) Strong and delocalized integrin a6 staining is detected in K5-IKKa tumors while WT tumors show integrin a6 basal
expression. (F, F’) Twist is expressed in Tg tumors while it is not detected in WT tumors. (G, G’) Higher proliferation rate (measured as BrdU
incorporation) is detected in Tg tumors (both in the basal and suprabasal layers) compared to the lower proliferating cells found in the basal layer of
WT tumors. (H, H’) Increased Caspase 3 cleaved (Casp3C) staining in K5-IKKa tumors compared to that in WT tumors.
doi:10.1371/journal.pone.0021984.g005
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important difference, because the tumorigenic properties of skin
tumors strongly depend on the cell type targeted being the
expression of a potential tumoral promoter more harmful in basal
cells than in terminally differentiated cells [62]. Other studies on
the role of IKKa in skin tumorigenesis have been performed in
IKKa+/2 mice and show that these animals develop more
carcinomas with a lower latency period [13]. However, these mice
are defective in IKK expression in both epidermis and dermis, and
increasing evidences support the contribution of the tumor stroma
to some of the most malignant characteristics of epithelial tumors
[63]; therefore through this approach it is not possible to discern
the role that the expression of IKKa specifically in keratinocytes
plays for skin carcinogenesis. A different approach to this study
would be the use of conditional knockout mice lacking IKKa
specifically in keratinocytes. These mice have been generated by
two different groups and the skin phenotypes obtained are
completely different: while one model exhibits an hyperplastic
skin with absence of terminal differentiation [12], the other shows
a nearly normal skin with terminal differentiation and no signs of
hyperplasia [11] being the reasons for this discrepancy not
understood. Therefore, although skin carcinogenesis assays
showing increased tumorigenesis in the IKKa conditional mice
exhibiting a skin phenotype have been reported [12], the absence
of the same experiments in the other IKKa conditional mice
model casts doubts on the conclusiveness of the results.
Taking into account the different results published, it seems that
the role that IKKa plays in carcinogenesis could depend on the
type of tumor, the cell targeted in each tumor and the strain of
mice employed in the studies. Our present study supposes a
different approach for study the role of IKKa in skin carcinogen-
esis, targeting IKKa to the basal keratinocytes of the epidermis.
Our results showing the increase in the malignant potential of skin
tumors developed in vivo, in transgenic mice overexpressing IKKa
in keratinocytes, are in line and strengthen our previous findings
showing the enhanced aggressiveness of skin tumors arising after
injection of tumor epidermal cells overexpressing IKKa into nude
mice [5]. We have found that increased IKKa expression levels in
the basal layer of the epidermis and ORS of the hair follicles of
transgenic mice leads to alterations that originate lesions of higher
malignant potential than those developed in WT mice when
subjected to aberrant mitogenic stimuli. We have found that the
altered expression of cyclin D1, maspin and integrin-a6 in skin of
transgenic mice provide, at least in part, the molecular bases of the
increase in the malignant potential of carcinomas originated in
skin of K5-IKKa Tg mice.
Supporting Information
Figure S1 Graphical representation of the number of tumors
developed in WT and Tg-K5-IKKa mice in the two skin
carcinogenesis approaches. (A) K5-IKKa and WT 9-week-old
mice (9 animals respectively) were subjected to DMBA/TPA
carcinogenesis assay. Tumors were traced until week 26, when
they were collected. (B) Double transgenic K5-IKKa-TgAC and
WT-TgAC 9-week-old mice (11 animals respectively) were treated
twice weekly with topical applications of TPA. Tumors were
traced until week 30, when they were collected. No differences
were found between number of tumors developed in WT and Tg
animals in both approaches.
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